Ohio State Navbar

Sign In

RSS Feed Regenerative Medicine News


Juventas Therapeutics doses first patient in Phase II STOP-HF trial 

 

 

Juventas Therapeutics doses first patient in Phase II STOP-HF trial
August 20, 2012 - (The Sacramento Bee) - "Juventas Therapeutics, a privately-held clinical-stage company developing novel regenerative therapies for treatment of cardiovascular disease, reports treating the first patient in its STOP-HF trial. The 90-patient, placebo-controlled, randomized double-blinded Phase II study is evaluating the safety and efficacy for JVS-100 in patients with late stage heart failure."  Read Full Article

 

Posted on 23-Aug-12 by Toto, Brent
Tags: Science and Industry News
 
Trackback Url  |  Link to this post | Bookmark this post with: